SCLX
Scilex Holding CompanyNASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
-0.49
P/S
1.57
EV/EBITDA
-0.40
DCF Value
$-186.62
FCF Yield
37.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
68.6%
Operating Margin
-652.4%
Net Margin
-931.2%
ROE
181.1%
ROA
-162.0%
ROIC
948.4%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $10.6M | $-257.2M | $-22.17 |
| Q2 2025 | $9.9M | $-86.1M | $-7.42 |
| Q1 2025 | $5.0M | $-26.1M | $-2.26 |
| Q4 2024 | $14.9M | $-6.5M | $-1.23 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
1.42
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.